GRALISE is supplied as tablets containing 300 mg or 600 mg of gabapentin
The recommended maintenance dose of NEURONTIN in patients 5 to 11 years of age is 25 mg/kg/day to 35 mg/kg/day, given in three divided doses
Dosages up to 50 mg/kg/day have been well tolerated in a long-term clinical study
The U
recommended maintenance dose of gabapentin oral solution in patients 5 to 11 years of age is 25 mg/kg/day to 35 mg/kg/day, given in three divided doses
The PI is different from the Patient Package Insert (PPI), which contains information intended for patients, notwithstanding that the PPI may be required as part
Patients taking gabapentin were required to discontinue gabapentin treatment 1 week prior to entering baseline
Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40
Body System/ Adverse Event
Dosages up to 2400 mg/day have been well tolerated in long-term clinical studies
NEURONTIN may be administered as the oral solution, capsule, or tablet, or using combinations of these formulations
Dosages up to 50 mg/kg/day have been well tolerated in a long-term clinical study
The log of the partition coefficient (n-octanol/ 0
Gabapentin capsules should be swallowed whole
Doses of 3600 mg/day have also been administered to a small
Gabapentin may be administered as the oral solution, capsule, or tablet, or using combinations of these formulations
1 ) Dose can be titrated up as
1) (gabapentin enacarbil) Extended-Release Tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults
2
Includes: indications, dosage, adverse reactions and pharmacology
Because NEURONTIN is eliminated solely by renal excretion, dosage adjustments are recommended for patients with renal impairment (including elderly patients with declining renal function) and patients undergoing hemodialysis
The starting dose is 300 mg three times a day
The starting dose range is 10 mg/kg/day to 15 mg/kg/day, given in three divided doses, and the recommended maintenance dose reached by upward titration over a period of approximately 3 days
During an 8-week baseline period, patients had to experience at least 6 partial-onset seizures with no seizure-free period exceeding 4 weeks
TEVA-GABAPENTIN (gabapentin) is indicated as adjunctive therapy for the management of patients with epilepsy who are not satisfactorily controlled by conventional therapy
They may have withdrawal effects when they stop using Neurontin (see section 3, “How to take Neurontin” and “If you stop taking Neurontin”)